279 related articles for article (PubMed ID: 21440623)
1. In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate.
Elsby R; Fox L; Stresser D; Layton M; Butters C; Sharma P; Smith V; Surry D
Eur J Pharm Sci; 2011 May; 43(1-2):41-9. PubMed ID: 21440623
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
3. Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4.
El-Sheikh AA; Greupink R; Wortelboer HM; van den Heuvel JJ; Schreurs M; Koenderink JB; Masereeuw R; Russel FG
Transl Res; 2013 Dec; 162(6):398-409. PubMed ID: 24036158
[TBL] [Abstract][Full Text] [Related]
4. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters.
Caetano-Pinto P; Jamalpoor A; Ham J; Goumenou A; Mommersteeg M; Pijnenburg D; Ruijtenbeek R; Sanchez-Romero N; van Zelst B; Heil SG; Jansen J; Wilmer MJ; van Herpen CML; Masereeuw R
Mol Pharm; 2017 Jun; 14(6):2147-2157. PubMed ID: 28493713
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Methotrexate Uptake via Organic Anion Transporters OAT1 and OAT3 by Glucuronides of Nonsteroidal Anti-inflammatory Drugs.
Iwaki M; Shimada H; Irino Y; Take M; Egashira S
Biol Pharm Bull; 2017; 40(6):926-931. PubMed ID: 28566636
[TBL] [Abstract][Full Text] [Related]
7. Interaction of hydroxycinnamic acids and their conjugates with organic anion transporters and ATP-binding cassette transporters.
Wong CC; Barron D; Orfila C; Dionisi F; Krajcsi P; Williamson G
Mol Nutr Food Res; 2011 Jul; 55(7):979-88. PubMed ID: 21538853
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of
Parvez MM; Shin HJ; Jung JA; Shin JG
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223391
[No Abstract] [Full Text] [Related]
10. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3.
Huang C; Xia F; Xue L; Liu L; Bian Y; Jin Z; Miao L
Cancer Chemother Pharmacol; 2020 Feb; 85(2):433-441. PubMed ID: 31691080
[TBL] [Abstract][Full Text] [Related]
11. P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate.
Jia Y; Liu Z; Wang C; Meng Q; Huo X; Liu Q; Sun H; Sun P; Yang X; Ma X; Liu K
Toxicol Appl Pharmacol; 2016 Sep; 306():27-35. PubMed ID: 27377006
[TBL] [Abstract][Full Text] [Related]
12. The potential of Sutherlandia frutescens for herb-drug interaction.
Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
Kosa RE; Lazzaro S; Bi YA; Tierney B; Gates D; Modi S; Costales C; Rodrigues AD; Tremaine LM; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1179-1189. PubMed ID: 29880631
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients.
Kozaki T; Tagashira M; Yamanishi K; Ellis B; Kayanoki T; Ooishi R; Sugiyama K; Matsuda S; Tsuruta K; Kohira T; Tsurui K
Xenobiotica; 2015; 45(7):615-24. PubMed ID: 25579091
[TBL] [Abstract][Full Text] [Related]
15. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
16. Diclofenac and Its Acyl Glucuronide: Determination of In Vivo Exposure in Human Subjects and Characterization as Human Drug Transporter Substrates In Vitro.
Zhang Y; Han YH; Putluru SP; Matta MK; Kole P; Mandlekar S; Furlong MT; Liu T; Iyer RA; Marathe P; Yang Z; Lai Y; Rodrigues AD
Drug Metab Dispos; 2016 Mar; 44(3):320-8. PubMed ID: 26714763
[TBL] [Abstract][Full Text] [Related]
17. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices.
Nozaki Y; Kusuhara H; Kondo T; Iwaki M; Shiroyanagi Y; Nakayama H; Horita S; Nakazawa H; Okano T; Sugiyama Y
J Pharmacol Exp Ther; 2007 Sep; 322(3):1162-70. PubMed ID: 17578901
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
19. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
